Selection of appropriate anticancer therapy is critically dependent on an accurate prediction of the clinical behavior of individual neoplasms. In squamous cell carcinoma of the head and neck, this assessment is based largely on the anatomic location, size of the primary tumor, and the presence or absence of metastasis. These parameters do not address the biological properties of individual tumors, and consequently cannot readily distinguish between indolent and aggressive tumors with a given clinical stage. Furthermore, this staging system cannot predict likely responses to adjuvant treatments such as radiation or chemotherapy. The importance of more powerful biologic diagnostic tools becomes obvious given that 50,000-60,000 patients present with head, neck and upper esophageal cancer each year, and that 40% of these patients will die of their disease within 5 years. Despite the significant morbidity and mortality caused by these tumors, relatively little is known about their progression at the molecular level. This study will provide molecular biological data needed to develop more accurate diagnostic and prognostic tools. We will identify tumor suppressor genes whose mutation contributes to the disease process by detecting chromosomal deletions and rearrangements that result in the loss of the remaining wildtype allele of that gene. These chromosomal alterations manifest themselves through the use of heterozygosity for highly polymorphic genetic marker loci. We will detect these losses through the use of a relatively new molecular genetic mapping technique: polymerase chain reaction-based analysis of simple sequence repeat polymorphisms. Our findings will be correlated with patient outcome data to determine which chromosome losses have significant prognostic and diagnostic power. These findings will, in turn, form the basis for two longer term projects: 1) the high resolution mapping and eventual cloning of genes involved in squamous cell carcinoma progression, and 2) the development of molecular probes useable in clinical pathology laboratories. These probes will provide an essential part of a tumor staging system based on the biological as well as clinical properties of tumors, and the genes identified by the mapping studies may have eventual therapeutic value.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA058473-01
Application #
3202606
Study Section
Pathology B Study Section (PTHB)
Project Start
1993-03-01
Project End
1996-02-29
Budget Start
1993-03-01
Budget End
1994-02-28
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Washington University
Department
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Lau, Wei Ling; Scholnick, Steven B (2003) Identification of two new members of the CSMD gene family small star, filled. Genomics 82:412-5
Sun, P C; Uppaluri, R; Schmidt, A P et al. (2001) Transcript map of the 8p23 putative tumor suppressor region. Genomics 75:17-25
Sunwoo, J B; Sun, P C; Gupta, V K et al. (1999) Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. Oncogene 18:2651-5
Sun, P C; Schmidt, A P; Pashia, M E et al. (1999) Homozygous deletions define a region of 8p23.2 containing a putative tumor suppressor gene. Genomics 62:184-8
Scholnick, S B; El-Mofty, S K; Shaw, M E et al. (1998) Clinical correlations with allelotype in supraglottic squamous cancer. Otolaryngol Head Neck Surg 118:363-70
Kokoska, M S; Piccirillo, J F; el-Mofty, S K et al. (1996) Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 78:1693-700
Scholnick, S B; Haughey, B H; Sunwoo, J B et al. (1996) Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst 88:1676-82
Sunwoo, J B; Holt, M S; Radford, D M et al. (1996) Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. Genes Chromosomes Cancer 16:164-9
Sun, P C; el-Mofty, S K; Haughey, B H et al. (1995) Allelic loss in squamous cell carcinomas of the larynx: discordance between primary and metastatic tumors. Genes Chromosomes Cancer 14:145-8
Scholnick, S B; Sun, P C; Shaw, M E et al. (1994) Frequent loss of heterozygosity for Rb, TP53, and chromosome arm 3p, but not NME1 in squamous cell carcinomas of the supraglottic larynx. Cancer 73:2472-80